PharmaCyte Biotech, Inc.

PMCBNASDAQHealthcare● Active

$0.70

+$0.00(+0.00%)

Market Cap$4757046

P/E Ratio—

52W High$1.51

52W Low$0.63

Avg Volume196K

Open$0.71

Beta0.52

Overview

PharmaCyte Biotech, Inc. (PMCB) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · PMCB · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

∞

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 100%Active transactions only · RSU vesting excluded0% Sell ↓

PharmaCyte Biotech, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

PMCB insider buying and selling by quarter

PMCB insider selling · PMCB insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

875K438K0

2022 Q1

2022 Q3

2022 Q4

2023 Q4

2024 Q2

2025 Q2

2025 Q4

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · PMCB ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

PMCB executive sell shares · PMCB board member insider trading · PMCB insider trading SEC filing

Showing 16 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jan 7, 2026	Silverman Joshua CEO and President · Director	Purchase	40,000	$0.83	$33K	416,250	Form 4
Jan 6, 2026	Silverman Joshua CEO and President · Director	Purchase	30,000	$0.79	$24K	376,250	Form 4
Jan 5, 2026	Silverman Joshua CEO and President · Director	Purchase	30,000	$0.78	$23K	346,250	Form 4
Jan 7, 2026	SCHECHTER JONATHAN Director	Purchase	20,000	$0.84	$17K	192,500	Form 4
Jan 6, 2026	SCHECHTER JONATHAN Director	Purchase	20,000	$0.79	$16K	172,500	Form 4
Jan 5, 2026	SCHECHTER JONATHAN Director	Purchase	20,000	$0.78	$16K	152,500	Form 4
Dec 12, 2025	WEINSTEIN ROBERT Director	Award	75,000	—	—	75,000	Form 4
Dec 12, 2025	WEINSTEIN ROBERT Director	Other	33,750	$1.02	$34K	41,250	Form 4
Dec 12, 2025	WALKER WAYNE REMELL Director	Award	37,500	—	—	37,500	Form 4
Dec 12, 2025	WALKER WAYNE REMELL Director	Other	16,875	$1.02	$17K	20,625	Form 4
Dec 12, 2025	Silverman Joshua CEO and President · Director	Award	575,000	—	—	575,000	Form 4
Dec 12, 2025	Silverman Joshua CEO and President · Director	Other	258,750	$1.02	$264K	316,250	Form 4
Dec 12, 2025	SCHECHTER JONATHAN Director	Award	150,000	—	—	200,000	Form 4
Dec 12, 2025	SCHECHTER JONATHAN Director	Other	67,500	$1.02	$69K	132,500	Form 4
Dec 12, 2025	Abecassis Michael M Director	Award	37,500	—	—	39,167	Form 4
Dec 12, 2025	Abecassis Michael M Director	Other	16,875	$1.02	$17K	22,292	Form 4

Silverman Joshua

CEO and President · Director

Purchase

Date

Jan 7

40,000

Price

$0.83

Value

$33K

View Form 4 on SEC.gov

Silverman Joshua

CEO and President · Director

Purchase

Date

Jan 6

30,000

Price

$0.79

Value

$24K

View Form 4 on SEC.gov

Silverman Joshua

CEO and President · Director

Purchase

Date

Jan 5

30,000

Price

$0.78

Value

$23K

View Form 4 on SEC.gov

SCHECHTER JONATHAN

Director

Purchase

Date

Jan 7

20,000

Price

$0.84

Value

$17K

View Form 4 on SEC.gov

SCHECHTER JONATHAN

Director

Purchase

Date

Jan 6

20,000

Price

$0.79

Value

$16K

View Form 4 on SEC.gov

SCHECHTER JONATHAN

Director

Purchase

Date

Jan 5

20,000

Price

$0.78

Value

$16K

View Form 4 on SEC.gov

WEINSTEIN ROBERT

Director

Award

Date

Dec 12

75,000

Price

—

Value

—

View Form 4 on SEC.gov

WEINSTEIN ROBERT

Director

Other

Date

Dec 12

33,750

Price

$1.02

Value

$34K

View Form 4 on SEC.gov

WALKER WAYNE REMELL

Director

Award

Date

Dec 12

37,500

Price

—

Value

—

View Form 4 on SEC.gov

WALKER WAYNE REMELL

Director

Other

Date

Dec 12

16,875

Price

$1.02

Value

$17K

View Form 4 on SEC.gov

Silverman Joshua

CEO and President · Director

Award

Date

Dec 12

575,000

Price

—

Value

—

View Form 4 on SEC.gov

Silverman Joshua

CEO and President · Director

Other

Date

Dec 12

258,750

Price

$1.02

Value

$264K

View Form 4 on SEC.gov

SCHECHTER JONATHAN

Director

Award

Date

Dec 12

150,000

Price

—

Value

—

View Form 4 on SEC.gov

SCHECHTER JONATHAN

Director

Other

Date

Dec 12

67,500

Price

$1.02

Value

$69K

View Form 4 on SEC.gov

Abecassis Michael M

Director

Award

Date

Dec 12

37,500

Price

—

Value

—

View Form 4 on SEC.gov

Abecassis Michael M

Director

Other

Date

Dec 12

16,875

Price

$1.02

Value

$17K

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About PMCB insider trading

PMCB insider trades

PharmaCyte Biotech, Inc. (PMCB) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Silverman Joshua (CEO and President · Director), SCHECHTER JONATHAN (Director), WEINSTEIN ROBERT (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. PMCB insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For PharmaCyte Biotech, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

PMCB insider trading · 5 questions

The insiders of PharmaCyte Biotech, Inc. (PMCB) include executives and directors such as Silverman Joshua (CEO and President · Director), SCHECHTER JONATHAN (Director), WEINSTEIN ROBERT (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

PMCB board member insider tradingwho are PMCB insidersPMCB insider rosterPharmaCyte Biotech, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026